Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB and Randomized Phase II Trial of Megestrol Acetate With or Without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer

NCT05538897 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05538897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05538897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB and Randomized Phase II Trial of Megestrol Acetate With or Without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 31, 2023
Completion date
January 31, 2027
Enrollment
96 (estimated)
Sites
152

Conditions

As the registry lists them; a condition with its own page is linked.

figo grade 1 endometrial endometrioid adenocarcinoma, figo grade 2 endometrial endometrioid adenocarcinoma, metastatic endometrial endometrioid adenocarcinoma, recurrent endometrial endometrioid adenocarcinoma